EP1551452A1 - Compositions et procedes pour traitement therapeutique - Google Patents

Compositions et procedes pour traitement therapeutique

Info

Publication number
EP1551452A1
EP1551452A1 EP03742338A EP03742338A EP1551452A1 EP 1551452 A1 EP1551452 A1 EP 1551452A1 EP 03742338 A EP03742338 A EP 03742338A EP 03742338 A EP03742338 A EP 03742338A EP 1551452 A1 EP1551452 A1 EP 1551452A1
Authority
EP
European Patent Office
Prior art keywords
composition
agent
antibody
fragment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742338A
Other languages
German (de)
English (en)
Other versions
EP1551452A4 (fr
Inventor
Janette Lazarovits
Abraham Nimrod
Hagit Hoch-Mar-Chaim
Avigdor Levanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of EP1551452A1 publication Critical patent/EP1551452A1/fr
Publication of EP1551452A4 publication Critical patent/EP1551452A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • the present invention relates to therapeutic and diagnostic compositions and methods, utilizing agents and antibodies, which may have anti-cancer activity, anti- metastatic activity, anti-le ⁇ kemia activity, anti-viral activity, anti-infection activity, and/or activity against other diseases, such as inflammatory diseases, diseases involving abnormal or pathogenic adhesion, thrombosis and/or restenosis, diseases involving abnormal or pathogenic aggregation, and autoimmune diseases, cardiovascular diseases, such as myocardial infarction, retinopathic diseases, diseases caused by sulfated tyrosine- dependent protein-protein interactions, and diseased cells generally.
  • diseases such as inflammatory diseases, diseases involving abnormal or pathogenic adhesion, thrombosis and/or restenosis, diseases involving abnormal or pathogenic aggregation, and autoimmune diseases
  • cardiovascular diseases such as myocardial infarction, retinopathic diseases, diseases caused by sulfated tyrosine- dependent protein-protein interactions, and diseased cells generally.
  • Tissue-selective targeting of therapeutic agents is an emerging discipline in the pharmaceutical industry. New cancer treatments based on targeting have been designed to increase the specificity and potency ofthe treatment, while reducing toxicity and enhancing overall efficacy.
  • Mouse monoclonal antibodies (MAbs) to tumor-associated antigens have been employed in an attempt to target toxin, radionucleotide, and chemotherapeutic conjugates to tumors.
  • differentiation antigens such as CD19, CD20, CD22 and CD25, have been exploited as cancer specific targets in treating hematopoietic malignancies.
  • this approach has several limitations. One limitation is the difficulty of isolating appropriate monoclonal antibodies that display selective binding.
  • a second limitation is the need for high antibody immunogenicity as a prerequisite for successful antibody isolation.
  • a third limitation is that the final product comprises non-human sequences, which gives rise to an immune response to the non-human material (e.g., human anti-mouse antibody-HAMA response).
  • the HAMA response often results in a shorter serum half-life and prevents repetitive treatments, thus diminishing the therapeutic value ofthe antibody.
  • This latter limitation has stimulated interest both in engineering chimeric or humanized monoclonal antibodies of murine origin, and in discovering human antibodies.
  • Another limitation of this approach is that it enables the isolation of only a single antibody species directed against only known and purified antigens. Moreover, this method is not selective insofar as it allows for the isolation of antibodies against cell surface markers that are present on normal, as well as on malignant, cells.
  • MAbs have many factors that influence the therapeutic efficacy of MAbs for treating cancer. These factors include specificity of antigen expression on tumor cells, level of expression, antigenic heterogeneity and accessibility ofthe tumor mass. Leukemia and lymphoma have been generally more responsive to treatment with antibodies than solid tumors, such as carcinomas. MAbs rapidly bind to leukemia and lymphoma cells in the bloodstream and easily penetrate to malignant cells in lymphatic tissue, thus making lymphoid tumors excellent candidates for MAb-based therapy. An ideal system entails identifying a MAb that recognizes a marker on the cell surface of stem cells that are producing malignant progeny cells.
  • Phage libraries are used to select random single chain Fvs (scFvs) that bind to isolated, pre-determined target proteins such as antibodies, hormones and receptors.
  • scFvs random single chain Fvs
  • target proteins such as antibodies, hormones and receptors.
  • antibody display libraries in general, and phage scFv libraries in particular, facilitates an alternative means of discovering unique molecules for targeting specific, yet unrecognized and undetermined, cell surface moieties.
  • Leukemia, lymphoma, and myeloma are cancers that originate in the bone marrow and lymphatic tissues and are involved in uncontrolled growth of cells.
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease that is defined by specific clinical - and immunological characteristics. Like other forms of ALL, the definitive cause of most cases of B-cell ALL (B-ALL) is not known although, in many cases, the disease results from acquired genetic alterations in the DNA of a single cell, causing it to become abnormal and multiply continuously. Prognosis for patients afflicted with B-ALL is significantly worse than for patients with other leukemias, both in children and in adults.
  • AML Acute Myelogenous Leukemia
  • AML is a heterogeneous group of neoplasms with a progenitor cell that, under normal conditions, gives rise to terminally differentiated cells ofthe myeloid series (erythrocytes, granulocytes, monocytes, and platelets).
  • AML is associated with acquired genetic alterations that result in replacement of normally differentiated myeloid cells with relatively undifferentiated blasts, exhibiting one or more type of early myeloid differentiation.
  • AML generally evolves in the bone marrow and, to a lesser degree, in the secondary hematopoietic organs.
  • AML primarily affects adults, peaking in incidence between the ages of 15-40, but it is also known to affect both children and older adults. Nearly all patients with AML require treatment immediately after diagnosis to achieve clinical remission, in which there is no evidence of abnormal levels of circulating undifferentiated blast cells.
  • an additional anti-CD33 antibody (HumM195), currently in clinical trials, was conjugated to several cytotoxic agents, including the gelonin toxin (McGraw et al, Cancer Immunol. Immunother, 39, 367-374 (1994)) and radioisotopes I31 I (Caron et al, Blood 83, 1760-1768 (1994)), 90 Y (Jurcic et al., Blood Supplement, 92, 613a (1998)) and 2I3 Bi (Humm et al, Blood Supplement, 38:231P (1997)).
  • gelonin toxin McGraw et al, Cancer Immunol. Immunother, 39, 367-374 (1994)
  • radioisotopes I31 I Caron et al, Blood 83, 1760-1768 (1994)
  • 90 Y Jurcic et al., Blood Supplement, 92, 613a (1998)
  • 2I3 Bi Human Immunot al, Blood Supplement, 38:231P (1997)).
  • a chimeric antibody against the leukocyte antigen CD45 (cHuLym3) is in clinical studies for treatment of human leukemia and lymphoma (Sun et al, Cancer Immunol. Immunother., 48, 595-602 (2000)).
  • ADCC antibody dependent cell-mediated cytotoxicity
  • phage display technology enables the isolation of scFvs comprising fully human sequences.
  • a fully human antibody against the human TGFb2 receptor based on an scFv clone derived from phage display technology was recently developed. This scFv, converted into a fully human IgG4 that is capable of competing with the binding of TGFb2 (Thompson et al, J. Immunol Methods, 227, 17-29 (1999)), has strong anti- proliferative activity.
  • Platelets, fibrinogen, GPIb, selectins, and P-Selectin Glycoprotein Ligand-1 each play an important role in several pathogenic conditions or disease states, such as abnormal or pathogenic inflammation, abnormal or pathogenic immune reactions, autoimmune reactions, metastasis, abnormal or pathogenic adhesion, thrombosis and/or restenosis, and abnormal or pathogenic aggregation.
  • pathogenic conditions or disease states such as abnormal or pathogenic inflammation, abnormal or pathogenic immune reactions, autoimmune reactions, metastasis, abnormal or pathogenic adhesion, thrombosis and/or restenosis, and abnormal or pathogenic aggregation.
  • antibodies that cross-react with platelets and with these molecules would be useful in the diagnosis and treatment of diseases and disorders involving these and other pathogenic conditions.
  • Platelets are well-characterized components ofthe blood system and play several important roles in hemostasis, thrombosis and/or restenosis, and restenosis. Damage to blood vessel sets in motion a process known as hemostasis, which is characterized by series of sequential events.
  • the initial reaction to damaged blood vessels is the adhesion of platelets to the affected region on the inner surface ofthe vessel.
  • the next step is the aggregation of many layers of platelets onto the previously adhered platelets, forming the hemostatic plug. This clump of platelets seals the vessel wall.
  • the hemostatic plug is strengthened by the deposition of fibrin polymers. The clot is degraded only when the damage has been repaired.
  • Tumor metastasis is perhaps the most important factor limiting the survival of cancer patients. Accumulated data indicate that the ability of tumor cells to interact with host platelets represents one ofthe indispensable determinants of metastasis. Leslie Oleksowicz, Z.M., "Characterization Of Tumor-Induced Platelet Aggregation: The Role Of Immunorelated GPIb And GPIIb/IIIa Expression By MCF-7 Breast Cancer Cells," Thrombosis Research 79: 261-274 (1995).
  • Each step in the process of hemostasis requires the presence of receptors on the platelet surface.
  • One receptor that is important in hemostasis is the glycoprotein Ib-IX complex (also known as CD42). This receptor mediates adhesion (initial attachment) of platelets to the blood vessel wall at sites of injury by binding von Willebrand factor (vWF) in the subendothelium. It also has crucial roles in two other platelet functions important in hemostasis: (a) aggregation of platelets induced by high shear in regions of arterial stenosis and (b) platelet activation induced by low concentrations of thrombin.
  • the GPIb-IX complex is one ofthe major components ofthe outer surface ofthe platelet plasma membrane.
  • the GPIb-IX complex comprises three membrane-spanning polypeptides- a disulfide-linked 130 kDa ⁇ -chain and 25 kDa ⁇ -chain of GPIb and noncovalently associated GPIX (22 kDa). All four units are presented in equimolar amounts on the platelet membrane, for efficient cell-surface expression and function of CD42 complex, indicating that proper assembly ofthe three subunits into a complex is required for full expression on the plasma membrane.
  • the ⁇ -chain of GPIb consists of three distinct structural domains: (1) a globular N-terminal peptide domain containing leucine-rich repeat sequences and Cys-bonded flanking sequences; (2) a highly glycosylated mucin-like macroglycopeptide domain; and (3) a membrane-associated C- terminal region that contains the disulfide bridge to GPIb ⁇ and transmembrane and cytoplasmic sequences.
  • vWF and thrombin-binding domain of the GPIb-IX complex reside in a globular region that encompasses approximately 300 amino acids at the amino terminus. of GPIb ⁇ .
  • the human platelets GPIb-IX complex is a key membrane receptor mediating both platelet function and reactivity. Recognition of subendothelial-bound vWF by GPIb allows platelets to adhere to damaged blood vessels. Further, binding of vWF to GPIb ⁇ also induces platelet activation, which may involve the interaction of a cytoplasmic domain ofthe GPIb-IX with cytoskeleton or phospolipase A2. Moreover, GPIb ⁇ contains a high-affinity binding site for ⁇ -thrombin, which, by an as-yet poorly defined mechanism, facilitates platelet activation.
  • the N-terminal globular domain of GPIb ⁇ contains a cluster of negatively charged amino.
  • Several lines of evidence indicate that, in transfected CHO cells expressing GPIb- IX complex and in platelet GPIb ⁇ , the three tyrosine residues contained in this domain (Tyr-276, Tyr-278, and Tyr-279) undergo sulfation.
  • Protein sulfation is a widespread posttranslational modification that involves enzymatic covalent attachment of sulfate, either to sugar side chains or to the polypeptide backbone. This modification occurs in the trans-Golgi compartment and, therefore affects only protein that traverses this compartment.
  • proteins include secretory proteins, proteins targeted for granules, and the extracellular regions of plasma membrane proteins.
  • Tyrosine is an amino acid residue presently known to undergo sulfation. J.W. Kehoe et al, Chemistry and Biol 1: R57-R61 (2000).
  • Other amino acids, for example threonine may perhaps also undergo sulfation, particularly in diseased cells.
  • GPIb ⁇ CD42
  • vWF subendothelium
  • the P-, E-, and L- Selectins are a family of adhesion molecules that, among other functions, mediate rolling of leukocytes on vascular endothelium.
  • P-Selectin is stored in granules in platelets and is transported to the surface after activation by thrombin, histamine, phorbol ester, or other stimulatory molecules.
  • P-Selectin is also expressed on activated endothelial cells.
  • E-Selectin is expressed on endothelial cells,' and L-Selectin is expressed on neutrophils, monocytes, T cells, and B cells.
  • PSGL-1 (also called CD162) is a mucin glycoprotein ligand for P-Selectin, E- Selectin, and L-Selectin.
  • PSGL-1 is a disulfide-linked homodimer that has a PACE (Paired Basic Amino Acid Converting Enzymes) cleavage site.
  • PSGL-1 also has three potential tyrosine sulfation sites followed by approximately 15 decamer repeats that are high in proline, serine, and threonine.
  • the extracellular portion of PSGL-1 contains three N-linked glycosylation sites and has numerous sialylated, fucosylated O-linked oligosaccharide branches. K.L.
  • PSGL-1 has 361 residues in HL60 cells, with a 267 residue extracellular region, a 25 residue trans-membrane region, and a 69 residue intracellular region.
  • the sequence encoding PSGL-1 is in a single exon, so alternative splicing should not be possible.
  • PSGL-1 in HL60 cells, and in most cell lines has 15 consecutive repeats of a 10 residue consensus sequences present in the extracellular region, but there are 14 and 16 repeats of this sequence, as well, in polymorphonuclear leukocytes, monocytes, and several other cell lines, including most native leukocytes.
  • PSGL-1 forms a disulfide- bonded homodimer on the cell surface.
  • PSGL-1 is expressed on neutrophils as a dimer, with apparent molecular weight of both 250 kDa and 160 kDa, whereas on HL60 the dimeric form is -220 kDa. When analyzed under reducing conditions, each subunit is reduced by half. Differences in molecular mass may be due to polymorphisms in the molecule caused by the presence of different numbers of decamer repeats. Leukocyte Typing VI. Edited by T. Kishimoto et al. (1997).
  • PSGL-1 is expressed on most blood leukocytes, such as neutrophils, monocytes, leukocytes, subset of B cells, and all T cells and mediates rolling of neutrophils on P- Selectin. Leukocyte Typing VI. Edited by T. Kishimoto et al. (1997). PSGL-1 may also mediate neutrophil-neutrophil interaction via binding with L-Selectin, thereby mediating inflammation. Snapp, et al, Blood 91(1): 154-64 (1998).
  • PSGL-1 mediates rolling of leukocytes on activated endothelium, on activated platelets, and on other leukocytes and inflammatory sites.
  • KPL1 A commercially available monoclonal antibody to human PGSL-1 , KPL1 , was generated and shown to inhibit the interactions between PGSL-1 and P-selectin and between PGSL-1 and L-selectin.
  • the KPL1 epitope was mapped to the tyrosine sulfation consensus motif of PGSL-1 (YEYLDYD). KPL1 recognizes only this particular epitope and does not cross-react with sulfated epitopes present on other cells, such as B-CLL cells, AML cells, metastatic cells, multiple myeloma cells, and the like.
  • Leukocyte rolling is important in inflammation, and interaction between P-Selectin (expressed by activated endothelium and on platelets, which may be immobilized at sites of injury) and PSGL-1 is instrumental for tethering and rolling of leukocytes on vessel walls.
  • Platelets are also involved in the process of metastasis; when metastatic cancer cells enter the blood stream, multicellular complexes composed of platelets and leukocytes coating the tumor cells are formed. These complexes, which may be referred to as microemboli, aid the tumor cells in evading the immune system.
  • the coating of tumor cells by platelets requires expression of P-selectin by the platelets.
  • PSGL-1 and GPIb share structural similarity, having mucin-like, highly glycosylated ligand binding regions. Afshar-Kharghan, et al, Blood 97(10): 3306-7 (2001).
  • PSGL-1 has been found on all leukocytes: neutrophils, monocytes, lymphocytes, activated peripheral T-cells, granulocytes, eosinophils, platelets and on some CD34 positive stem cells and certain subsets of B-cells.
  • P-Selectin is selectively expressed on activated platelets and endothelial cells. Interaction between P-Selectin and PSGL-1 promotes rolling of leukocytes on vessel walls, and abnormal accumulation of leukocytes at vascular sites results in various pathological inflammations. Stereo-specific contributions of individual tyrosine sulfates on PSGL-1 are important for the binding of P- Selectin to PSGL-1.
  • Normal fibrinogen which is the more abundant form (comprising -90% ofthe fibrinogen found in the body), is composed of two identical 55 kDa alpha ( ⁇ ) chains, two identical 95 kDa beta ( ⁇ ) chains, and two identical 49.5 kDa gamma ( ⁇ ) chains.
  • Normal variant fibrinogen which is the less abundant form (comprising -10% ofthe fibrinogen found in the body), is composed of two identical 55 kDa alpha ( ⁇ ) chains, two identical 95 kDa beta ( ⁇ ) chains, one 49.5 kDa gamma ( ⁇ ) chain, and one 50.5 kDa gamma prime ( ⁇ ') chain.
  • the gamma and gamma prime chains are both coded for by the same gene, with alternative splicing occurring at the 3' end.
  • Normal gamma chain is composed of amino acids 1-411.
  • Normal variant gamma prime chain is composed of 427 amino acids: amino acids 1-407 are the same as those in the normal gamma chain, and amino acids 408-427 are VRPEHPAETEYDSLYPEDDL. This region is normally occupied with thrombin molecules.
  • Fibrinogen is converted into fibrin by the action of thrombin in the presence of ionized calcium to produce coagulation ofthe blood. Fibrin is also a component of thrombi, and acute inflammatory exudates.
  • Platelets, and molecules that play important roles in cell-cell interactions, cell-matrix interactions, platelet-platelet interactions, platelet-cell interactions, platelet-matrix interactions, cell rolling and adhesion, and hemostasis also play important roles in pathogenic conditions or disease states, such as abnormal or pathogenic inflammation, abnormal or pathogenic immune reactions, autoimmune reactions, metastasis, abnormal or pathogenic adhesion, thrombosis and/or restenosis, and abnormal or pathogenic aggregation.
  • pathogenic conditions or disease states such as abnormal or pathogenic inflammation, abnormal or pathogenic immune reactions, autoimmune reactions, metastasis, abnormal or pathogenic adhesion, thrombosis and/or restenosis, and abnormal or pathogenic aggregation.
  • antibodies that cross- react with platelets and with these molecules are useful in the diagnosis and treatment of diseases and disorders involving these and other pathogenic conditions.
  • compositions of an antibody, or fragment thereof, and an agent including an agent such as an anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti- autoimmune, anti-aggregation, anti-bacterial, anti-viral, or anti-inflammatory agent.
  • an agent such as an anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti- autoimmune, anti-aggregation, anti-bacterial, anti-viral, or anti-inflammatory agent.
  • the present invention provides a composition having an agent and an antibody, or fragment thereof.
  • the present inventive compositions are such that the agent can be complexed with the antibody, or fragment thereof; the agent can be combined with the antibody, or fragment thereof; or the agent can be conjugated to an antibody, or fragment thereof.
  • the antibodies, or fragments thereof, ofthe present inventive compositions can be present as complexes or aggregates of one or more antibodies, or fragments.
  • the agent and/or the antibody, or fragment thereof can be present in a sub-clinical amount.
  • This sub-clinical amount can be insufficient to alter effectively susceptibility to agents, especially susceptibility of diseased cells.
  • the agent can be an anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti- adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, antibacterial, anti-viral, or anti-inflammatory agent.
  • the agent is an anfhracycline or a derivative thereof, which can be doxorubicin, daunorubicin, idarubicin, morpholinodoxorubicin, morpholinodaunorubicin, methoxymorpholinyldoxorubicin, or derivatives or combinations thereof.
  • the agent is doxorubicin or a derivative thereof.
  • the sub-clinical amount ofthe agent can be insufficient to inhibit effectively cell rolling, inflammation, auto-immune disease, thrombosis, restenosis, metastasis, or survival, growth, and/or replication of tumor cells or leukemia cells.
  • the sub-clinical amount ofthe agent can be insufficient to inhibit effectively an increase in the number of tumor cells in a patient having a tumor or inhibit an increase in the number of leukemia cells in a patient having leukemia.
  • the sub-clinical amount ofthe agent can be insufficient to decrease effectively the number of tumor cells in a patient having a tumor or decrease effectively the number of leukemia cells in a patient having leukemia.
  • the sub-clinical amount ofthe agent can be insufficient to increase effectively mortality of tumor cells or leukemia cells, increase effectively susceptibility of tumor cells to damage by anti-cancer agents, or increase effectively susceptibility of leukemia cells to damage by anti-leukemia agents.
  • the sub- clinical amount ofthe agent can be insufficient to inhibit effectively cell-cell, cell-matrix, platelet-matrix, platelet-platelet, and/or cell-platelet complex formation, aggregation, or adhesion.
  • the antibody, or fragment thereof, ofthe present inventive compositions can have the binding capabilities of an scFv antibody fragment of SEQ ID NO:l, SEQ ID NO:2, or SEQ ID NO:3.
  • the antibody, or fragment thereof can have the binding capabilities of a peptide or polypeptide, wherein the peptide or polypeptide has a first hypervariable region having SEQ ID NO:4.
  • Such a peptide or polypeptide also can further have a second hypervariable region having SEQ ID NO:5 and/or a third hypervariable region having SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.
  • the antibody, or fragment thereof can be an scFv or an Fab fragment.
  • composition ofthe present invention can also have an agent and an antibody, or fragment thereof, wherein the antibody, or fragment thereof, binds to a peptide or polypeptide epitope of about 3 to about 126 amino acid residues in length, which peptide or polypeptide epitope has at least 2 acidic amino acids and at least one sulfated tyrosine residue.
  • the compositions ofthe present invention can have an agent and an antibody, or fragment thereof, wherein the antibody, or fragment thereof, binds to at least two different molecules selected from the group consisting of PSGL-1, fibrinogen gamma prime ( ⁇ '), GPIb ⁇ , heparin, lumican, complement compound 4 (CC4), interalpha inhibitor, and prothrombin.
  • compositions ofthe present invention can have an agent and an antibody, or fragment thereof, wherein the antibody, or fragment thereof, binds to at least two different molecules selected from the group consisting of PSGL-1, fibrinogen gamma prime ( ⁇ '), GPIb ⁇ , heparin, lumican, complement compound 4 (CC4), interalpha inhibitor, and prothrombin and that binds to at least one cell type selected from the group consisting of B cell leukemia cells, B-CLL cells, AML cells, multiple myeloma cells, and metastatic cells.
  • the antibody, or fragment thereof binds to at least two different molecules selected from the group consisting of PSGL-1, fibrinogen gamma prime ( ⁇ '), GPIb ⁇ , heparin, lumican, complement compound 4 (CC4), interalpha inhibitor, and prothrombin and that binds to at least one cell type selected from the group consisting of B cell leukemia cells, B-CLL cells, AML cells, multiple myeloma cells, and meta
  • compositions ofthe present invention can have an agent and an antibody, or fragment thereof, wherein the antibody, or fragment thereof, cross-reacts with two or more epitopes, each epitope comprising one or more sulfated tyrosine residues and at least one cluster of two or more acidic amino acids.
  • the antibody, or fragment thereof can be coupled to or complexed or combined with a vehicle or carrier that is coupled to or complexed or combined with more than one agent.
  • a vehicle or carrier can be selected from the group consisting of dextran, lipophilic polymers, hydrophilic polymers, HPMA, and liposomes.
  • the vehicle or carrier is a doxorubicin-decorated liposome.
  • the vehicle or carrier is polyethylene glycol (PEG) or dextran.
  • the present invention also provides various methods of administering a composition ofthe present invention to a patient in need thereof.
  • the present invention also provides methods of ameliorating the effects of a disease, preventing a disease, treating a disease, or inhibiting the progress of a disease by administering to a patient in need thereof any ofthe present inventive compositions.
  • the present invention provides a method of inhibiting cell rolling, inflammation, auto-immune disease, thrombosis, restenosis, metastasis, survival, growth and/or replication of tumor cells, growth and/or replication of leukemia cells, increase in the number of tumor cells in a patient having a tumor, or increase in the number of leukemia cells in a patient having leukemia.
  • the present invention provides methods of increasing the mortality rate of tumor cells, the mortality rate of leukemia cells, the susceptibility of diseased cells to damage by anti-disease agents, the susceptibility of tumor cells to damage by anti-cancer agents, or the susceptibility of leukemia cells to damage by anti-cancer agents. Further, the present invention provides methods of decreasing the number of tumor cells in a patient having a tumor, the number of leukemia cells in a patient having leukemia. Finally, the present invention provides methods of inhibiting cell-cell, cell-matrix, platelet- matrix, platelet-platelet, and/or cell-platelet complex formation, aggregation, or adhesion.
  • the present invention also provides a method of therapeutic treatment by administering to a patient in need thereof (i) an antibody, or fragment thereof, and (ii) an agent, wherein one or both ofthe antibody, or fragment thereof, and/or the agent is administered in a sub-clinical amount.
  • the agent and antibody, or fragment thereof can be conjugated, complexed, or administered in combination.
  • the agent can be administered separately, prior or subsequent to the antibody, or fragment thereof, or in any other sequence or arrangement and vice versa.
  • Antibodies or immunoglobulins (IgGs) are protein molecules that bind to antigen. They are composed of units of four polypeptide chains (2 heavy and 2 light) linked together by disulf ⁇ de bonds. Each ofthe chains has a constant and variable region. They can be divided into five classes, IgG, IgM. IgA, IgD, and IgE, based on their heavy chain component. The IgG class encompasses several sub-classes including, but not restricted to, IgGi, IgG 2 , IgG , and IgG 4 . Immunoglobulins are produced in vivo by B lymphocytes and recognize a particular foreign antigenic determinant and facilitate clearing of that antigen.
  • Antibodies may be produced and used in many forms, including antibody complexes.
  • antibody complex or “antibody complexes” is used to mean a complex of one or more antibodies with another antibody or with an antibody fragment or fragments, or a complex of two or more antibody fragments.
  • antibody fragments include Fv, Fab, F(ab') 2 , F(ab'), Fc, and Fd fragments.
  • an Fv is defined as a molecule that is made up of a variable region of a heavy chain of a human antibody and a variable region of a light chain of a human antibody, which may be the same or different, and in which the variable region ofthe heavy chain is connected, linked, fused or covalently attached to, or associated with, the variable region ofthe light chain.
  • the Fv can be a single chain Fv (scFv) or a disulf ⁇ de stabilized Fv (dsFv).
  • An scFv is comprised ofthe variable domains of each ofthe heavy and light chains of an antibody, linked by a flexible amino-acid polypeptide spacer, or linker.
  • the linker may be branched or unbranched. Preferably, the linker is 0-15 amino acid residues, and most preferably the linker is (Gly Ser) 3 .
  • the Fv molecule itself is comprised of a first chain and a second chain, each chain comprising a first, second and third hypervariable region.
  • the hypervariable loops within the variable domains ofthe light and heavy chains are termed Complementary Determining Regions (CDR).
  • CDR1, CDR2 and CDR3 regions in each ofthe heavy and light chains are termed Complementary Determining Regions (CDR).
  • CDR1, CDR2 and CDR3 regions are believed to form the antigen binding site and can be specifically modified to yield enhanced binding activity.
  • the most variable of these regions in nature being the CDR3 region ofthe heavy chain.
  • the CDR3 region is understood to be the most exposed region ofthe Ig molecule and as shown and provided herein is the site primarily responsible for the selective and/or specific binding characteristics observed.
  • a fragment of an Fv molecule is defined as any molecule smaller than the original Fv that still retains the selective and/or specific binding characteristics ofthe original Fv.
  • fragments include but are limited to (1) a minibody, which comprises a fragment ofthe heavy chain only ofthe Fv, (2) a microbody, which comprises a small fractional unit of antibody heavy chain variable region (PCT Application No. PCT/IL99/00581), (3) similar bodies comprising a fragment ofthe light chain, and (4) similar bodies comprising a functional unit of a light chain variable region.
  • Fab fragment is a monovalent antigen-binding fragment of an immunoglobuhn.
  • a Fab fragment is composed ofthe light chain and part ofthe heavy chain.
  • a F(ab') 2 fragment is a bivalent antigen binding fragment of an immunoglobuhn obtained by pepsin digestion. It contains both light chains and part of both heavy chains.
  • a Fc fragment is a non-antigen-binding portion of an immunoglobuhn. It contains the carboxy-terminal portion of heavy chains and the binding sites for the Fc receptor.
  • a Fd fragment is the variable region and first constant region ofthe heavy chain of an immunoglobuhn.
  • a cassette as applied to polypeptides and as defined in the present invention, refers to a given sequence of consecutive amino acids that serves as a framework and is considered a single unit and is manipulated as such. Amino acids can be replaced, inserted into, removed, or attached at one or both ends. Likewise, stretches of amino acids can be replaced, inserted into, removed or attached at one or both ends.
  • epitope is used herein to mean the antigenic determinant or antigen site that interacts with an antibody, antibody fragment, antibody complex or a complex comprising a binding fragment thereof or T-cell receptor.
  • epitope is used interchangeably herein with the terms ligand, domain, and binding region.
  • Selectivity is herein defined as the ability of a targeting molecule to choose and bind one cell type or cell state from a mixture of cell types or cell states, all cell types or cell states of which may be specific for the targeting molecule.
  • affinity is a measure ofthe binding strength (association constant) between a receptor (e.g., one binding site on an antibody) and a ligand (e.g., antigenic determinant).
  • the strength ofthe sum total of noncovalent interactions between a single antigen-binding site on an antibody and a single epitope is the affinity ofthe antibody for that epitope.
  • Low affinity antibodies bind antigen weakly and tend to dissociate readily, whereas high-affinity antibodies bind antigen more tightly and remain bound longer.
  • the term “avidity” differs from affinity because the former reflects the valence ofthe antigen-antibody interaction.
  • antigen-antibody reaction is specific, in some cases antibodies elicited by one antigen can cross-react with another unrelated antigen. Such cross-reactions occur if two different antigens share a homologous or similar structure, epitope, or an anchor region thereof, or if antibodies specific for one epitope bind to an unrelated epitope possessing similar structure conformation or chemical properties.
  • a platelet is a disc-like cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently are circulating in the peripheral blood stream. Platelets have several physiological functions including a major role in clotting. A platelet contains granules in the central part and peripherally, clear protoplasm, but no definite nucleus.
  • Agglutination as used herein means the process by which suspended bacteria, cells, discs, or other particles of similar size are caused to adhere and form into clumps. The process is similar to precipitation but the particles are larger and are in suspension rather than being in solution.
  • aggregation means a clumping of platelets induced in vitro, and thrombin and collagen, as part of a sequential mechanism leading to the formation of a thrombus or hemostatic plug.
  • Conservative amino acid substitution is defined as a change in the amino acid composition by way of changing one or two amino acids of a peptide, polypeptide or protein, or fragment thereof.
  • the substitution is of amino acids with generally similar properties (e.g., acidic, basic, aromatic, size, positively or negatively charged, polar, non- polar) such that the substitutions do not substantially in a major way alter peptide, polypeptide or protein characteristics (e.g., charge, IEF, affinity, avidity, conformation, solubility) or activity.
  • Typical substitutions that may be performed for such conservative amino acid substitution may be among the groups of amino acids as follows:
  • G glycine
  • A alanine
  • V valine
  • L leucine
  • I isoleucine
  • A alanine
  • S serine
  • T threonine
  • H histidine
  • K lysine
  • R arginine
  • Conservative amino acid substitutions can be made in, as well as, flanking the hypervariable regions primarily responsible for the selective and/or specific binding characteristics ofthe molecule, as well as other parts ofthe molecule, e.g., variable heavy chain cassette. Additionally or alternatively, modification can be accomplished by reconstructing the molecules to form full-size antibodies, diabodies (dimers), triabodies (timers) and/or tetrabodies (tetramers) or to form minibodies or microbodies.
  • a phagemid is defined as a phage particle that carries plasmid DNA.
  • Phagemids are plasmid vectors designed to contain an origin of replication from a filamentous phage, such as ml 3 of fd. Because it carries plasmid DNA, the phagemid particle does not have sufficient space to contain the full complement ofthe phage genome.
  • the component that is missing from the phage genome is information essential for packaging the phage particle. In order to propagate the phage, therefore, it is necessary to culture the desired phage particles together with a helper phage strain that complements the missing packaging information.
  • a promoter is a region on DNA at which RNA polymerase binds and initiates transcription.
  • a phage display library (also termed phage peptide/antibody library, phage library, or peptide/antibody library) comprises a large population of phage (generally 10 8 - 10 9 ), each phage particle displaying a different peptide or polypeptide sequence. These peptide or polypeptide fragments may constructed to be of variable length.
  • the displayed peptide or polypeptide can be derived from, but need not be limited to, human antibody heavy or light chains.
  • a pharmaceutical composition refers to a formulation which comprises a peptide or polypeptide ofthe invention and a pharmaceutically acceptable carrier, excipient or diluent thereof.
  • a pharmaceutical agent refers to an agent that is useful in the prophylactic treatment or diagnosis of a mammal including, but not restricted to, a human, bovine, equine, porcine, murine, canine, feline, or any other warm-blooded animal.
  • the pharmaceutical agent is selected from the group comprising radioisotope, toxin, oligonucleotide, recombinant protein, antibody fragment, and anti-cancer agent.
  • anti-viral agents including acyclovir, ganciclovir and zidovudine
  • anti-thrombosis/restenosis agents including cilostazol, dalteparin sodium, reviparin sodium, and aspirin
  • anti-inflammatory agents including zaltoprofen, pranoprofen, droxicam, acetyl salicylic 17, diclofenac, ibuprofen, dexibuprofen, sulindac, naproxen, amtolmetin, celecoxib, indomethacin, rofecoxib, and nimesulid
  • anti-autoimmune agents including leflunomide, denileukin diftitox, subreum, WinRho SDF, defibrotide, and cyclophosphamide
  • anti-adhesion/anti-aggregation agents including limaprost, clorcromene, and
  • An anti-leukemia agent is an agent with anti-leukemia activity.
  • anti- leukemia agents include agents that inhibit or halt the growth of leukemic or immature pre-leukemic cells, agents that kill leukemic or pre-leukemic, agents that increase the susceptibility of leukemic or pre-leukemic cells to other anti-leukemia agents, and agents that inhibit metastasis of leukemic cells.
  • an anti-leukemia agent may also be agent with anti-angiogenic activity that prevents, inhibits, retards or halts vascularization of tumors.
  • the expression pattern of a gene can be studied by analyzing the amount of gene product produced under various conditions, at specific times, in various tissues, etc.
  • a gene is considered to be "over expressed" when the amount of gene product is higher than that found in a normal control, e.g., non-diseased control.
  • a given cell may express on its surface a protein having a binding site (or epitope) for a given antibody, but that binding site may be exist in a cryptic form (e.g., be sterically hindered or be blocked, or lack features needed for binding by the antibody) in the cell in a state, which may be called a first stage (stage I ).
  • Stage I may be, for example, a normal, healthy, non-diseased status.
  • the epitope may be exposed by, e.g., undergoing modifications itself, or being unblocked because nearby or associated molecules are modified or because a region undergoes a conformational change.
  • modifications include changes in folding, changes in post-translational modifications, changes in phospholipidation, changes in sulfation, changes in glycosylation, and the like.
  • Such modifications may occur when the cell enters a different state, which may be called a second stage (stage II).
  • second states, or stages include activation, proliferation, transformation, or in a malignant status.
  • the epitope may then be exposed, and the antibody may bind.
  • Peptido-mimetics are small molecules, peptides, polypeptides, lipids, polysaccharides or conjugates thereof that have the same functional effect or activity of another entity such as an antibody.
  • FIG. 1 graphically represents percent survival of MOLT-4 tumor-bearing mice as a function of time (days) following administration of doxorubicin and Yl alone, sequentially, or in combination.
  • the present invention relates to compositions and methods involving an agent and an antibody, or fragment thereof.
  • the compositions ofthe present invention can be such that one or more antibodies, or fragments thereof, are aggregated, associated, complexed, or combined with or conjugated, fused, or linked to one or more of various agents, such as drugs, toxins, and radioactive isotopes with, optionally, a pharmaceutically effective carrier, to form drug-peptide complexes, compositions, or conjugates having anti-disease and/or anti-cancer activity.
  • agents such as drugs, toxins, and radioactive isotopes
  • a pharmaceutically effective carrier such as a pharmaceutically effective carrier
  • Such complexes, combinations, conjugates may also be used for diagnostic purposes.
  • the agent and/or the antibody can be present in the composition in a sub-clinical amount.
  • sub-clinical amount is meant an amount that is less than the amount ofthe agent and/or antibody generally found to be clinically optimally effective when the agent and/or antibody is administered alone.
  • a sub-clinical amount can also mean an amount that is less than the amount required ofthe agent and/or antibody generally found to elicit a defined clinical response. It should be appreciated that sub-clinical is not intended to mean that the agent and/or antibody is clinically ineffective when administered according to the present inventive compositions and methods.
  • the sub-clinical amount ofthe agent can be insufficient to effectively alter susceptibility to agents, particularly susceptibility of diseased cells.
  • the sub-clinical amount ofthe agent can be insufficient to inhibit effectively cell rolling, inflammation, auto-immune disease, thrombosis, restenosis, metastasis, or growth and/or replication of tumor cells or leukemia cells.
  • the sub-clinical amount ofthe agent can be insufficient to inhibit effectively an increase in the number of tumor cells in a patient having a tumor or inhibit an increase in the number of leukemia cells in a patient having leukemia.
  • the sub-clinical amount ofthe agent also can be insufficient to decrease effectively the number of tumor cells in a patient having a tumor or decrease effectively the number of leukemia cells in a patient having leukemia.
  • the sub-clinical amount ofthe agent can be insufficient to increase effectively mortality of tumor cells or leukemia cells, increase effectively susceptibility of tumor cells to damage by anti-cancer agents, or increase effectively susceptibility of leukemia cells to damage by anti-leukemia agents.
  • the sub-clinical amount ofthe agent can be insufficient to inhibit effectively cell-cell, cell-matrix, platelet-matrix, platelet-platelet, and/or cell-platelet complex formation, aggregation, or adhesion.
  • the present inventive compositions have an antibody, or fragment thereof, having the binding capabilities of an scFv antibody fragment of SEQ ID NO:l, SEQ ID NO:2, or SEQ ID NO:3.
  • the scFv fragment of SEQ ID NO:l has been designated Yl
  • the scFv fragment of SEQ ID NO:2 has been designated Y17
  • the scFv fragment of SEQ ID NO:3 has been designated L32.
  • These antibodies were identified by screening a human antibody phage library, which has diversity only in the heavy chain CDR3 regions.
  • the human scFv Yl and Y17 antibodies fixed human platelets were screened in order to identify antibodies that bind platelets.
  • L32 was screened against a leukemia cell to select specific antibodies that recognize leukemia cell surface determinants, wherein the specific receptor was not previously known or characterized. Using this same method, another antibody, L31, was identified.
  • antibodies useful in the present inventive composition were identified in U.S. Application Nos. 10/032,423; 10/032,037; 10/029,988; 10/029,926; 09/751,181 ; and 60/258,948 and International Application Nos. PCT/USO 1/49442 and PCT/USO 1/49440 using the same phage library.
  • Specific examples of antibodies disclosed in these applications include the Yl and Yl 7 antibodies.
  • the antibodies disclosed in these applications were discovered to specifically bind to an epitope found on proteins ofthe hematopoetic cells, which is sulfated at an N-terminal tyrosine and thought to be involved in cell migration, e.g., tumor metastasis.
  • the epitope for Yl antibody is located between amino acids 272 and 285 on glycocalicin, one ofthe subunits ofthe CD42 complex in which there is cluster of negatively charged amino acids, resulting from the sulfated groups, which are essential for the binding of Yl to glycocalicin.
  • Yl binds the N-terminal of PSGL-1, which is a receptor for E, L- and P-selectins, containing sulfated tyrosine residues accompanied by a cluster of negatively charged amino acids.
  • the Yl antibody binds to several molecules, such as the glycocalicin molecule on platelets, fibrinogen-gamma prime, the complement compound 4 of human plasma, and the PSGL-1 molecule on KG-1 cells, its affinity to primary leukemia cells derived from either AML or multiple myeloma (MM) patients is several magnitudes higher relative to the previously mentioned epitopes.
  • L32 antibody and the antibodies disclosed in the Y1/Y17 applications bind leukemic cells, although L32 binds to leukemic cells with approximately five times greater affinity than Yl . While the L32 and Yl/Yl 7 antibodies were all isolated from a common germ line (DP32) and L32 appears to bind the same sulfated epitope as Y1/Y17, L32 does not bind platelets and, moreover, does not affect platelet aggregation.
  • DP32 common germ line
  • the sulfated epitopes previously identified as binding to the preferred antibodies of the present invention are characterized by the presence of sulfated moieties, such as sulfated tyrosine residues or sulfated carbohydrate or lipid moieties, preferably within a cluster of two or more acidic amino acids, which are found on ligands and receptors that play important roles in such diverse processes as inflammation, immune reactions, infection, autoimmune reactions, metastasis, adhesion, thrombosis and/or restenosis, cell rolling, and aggregation.
  • sulfated moieties such as sulfated tyrosine residues or sulfated carbohydrate or lipid moieties, preferably within a cluster of two or more acidic amino acids, which are found on ligands and receptors that play important roles in such diverse processes as inflammation, immune reactions, infection, autoimmune reactions, metastasis, adhesion, thrombosis and/or restenosis, cell rolling,
  • Such epitopes are also found on diseased cells, such as B cell leukemia cells, B-CLL cells, AML cells, multiple myeloma cells, and metastatic cells. These epitopes are useful targets for the therapeutic mediation of these processes and for diagnostic procedures.
  • the antibodies ofthe present inventive compositions binds different molecules or epitopes involved in inflammation, such as PSGL-1, fibrinogen gamma prime ( ⁇ ? ), GPIb, heparin, lumican, complement compound 4 (CC4), interalpha inhibitor, and prothrombin.
  • the antibodies bind to an epitope present on at least one cell type involved in inflammation or tumorigenesis, including B-CLL cells, T-ALL cells, AML cells, B-leukemia cells, multiple myeloma cells, and metastatic cells.
  • the antibodies the present inventive compositions bind to epitopes on a lipid, carbohydrate, peptide, glycolipid, glycoprotein, lipoprotein, and/or lipopolysaccharide molecule.
  • Such epitopes preferably have at least one sulfated moiety.
  • the antibodies cross-react with two or more epitopes, each epitope having one or more sulfated tyrosine residues, and at least one cluster of two or more acidic amino acids, an example of which is PSGL-1.
  • the antigen-binding site is complementary to the structure ofthe epitopes to which the antibodies bind; therefore these binding sites are referred to as complementarity-determining regions (CDRs).
  • CDRs complementarity-determining regions
  • the most variable of these regions is the CDR3 region ofthe heavy chain.
  • the CDR3 region is understood to be the most exposed region ofthe Ig molecule and, as provided herein, has a central role in determining the selective and/or specific binding characteristics observed.
  • the antibody, or fragment thereof has a first hypervariable region (CDR3) of SEQ ID NO:4.
  • the antibody, or fragment thereof has a second hypervariable region (CDR2) of SEQ ID NO:5.
  • the antibody, fragment thereof has a third hypervariable region (CDR1) of SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.
  • CDRs may also be inserted into cassettes to produce antibodies.
  • a cassette refers to a given sequence of consecutive amino acids that serves as a framework and is considered a single unit and is manipulated as such. Amino acids can be replaced, inserted into, removed, or attached at one or both ends. Likewise, stretches of amino acids can be replaced, inserted into, removed, or attached at one or both ends.
  • the amino acid sequence ofthe cassette may ostensibly be fixed, whereas the replaced, inserted, or attached sequence can be highly variable.
  • the cassette can be comprised of several domains, each of which encompasses a function crucial to the final construct.
  • the cassette of a particular embodiment ofthe present invention comprises, from the N-terminus, framework region 1 (FR1), CDR1, framework region 2 (FR2), CDR2, framework region 3 (FR3), and framework region 4 (FR4).
  • FR1 framework region 1
  • FR2 framework region 2
  • FR3 framework region 3
  • FR4 framework region 4
  • the CDR2 and CDR1 hypervariable regions ofthe cassette may be replaced or modified by non-conservative or, preferably, conservative amino acid substitutions.
  • amino acid sequences of ⁇ 25 amino acid residues described and detailed herein include within their scope one or two amino acid substitution(s) and that preferably the substitutions are conservative amino acid substitutions.
  • amino acid sequences of >25 amino acid residues described and detailed herein it is to be understood and considered as an embodiment ofthe invention that these amino acid sequences include within their scope an amino acid sequence with > 90% sequence similarity to the original sequence (Altschul et al., Nucleic Acids Res. 25: 3389-402 (1997)).
  • Similar or homologous amino acids are defined as non-identical amino acids which display similar properties, e.g., acidic, basic, aromatic, size, positively or negatively charged, polarity, non-polarity.
  • Percent amino acid similarity or homology or sequence similarity is determined by comparing the amino acid sequences of two different peptides or polypeptides. Antibody sequences were determined by DNA sequencing. The two sequences are aligned, usually by use of one of a variety of computer programs designed for the purpose, and amino acid residues at each position are compared. Amino acid identity or homology is then determined. An algorithm is then applied to determine the percentage amino acid similarity. It is generally preferable to compare amino acid sequences, due to the greatly increased sensitivity to detection of subtle relationships between the peptide, polypeptide or protein molecules. Protein comparison can take into account the presence of conservative amino acid substitutions, whereby a mismatch may yet yield a positive score if the non-identical amino acid has similar physical and/or chemical properties (Altschul et al. (1991), supra).
  • the three hypervariable regions of each ofthe light and heavy chains can be interchanged between the two chains and among the three- hypervariable sites within and/or between chains.
  • the present invention provides for a peptide or polypeptide having an antibody, or fragment thereof, a construct thereof, or a construct of a fragment.
  • antibodies include IgG, IgA, IgD, IgE, or IgM antibodies.
  • the IgG class encompasses several sub-classes including IgGi, IgG 2 , IgG 3 , and IgG 4 .
  • Antibodies may be provided in many forms, such as fragments, complexes, and multimers.
  • antibody fragments include Fv, scFv, dsFv, Fab, Fab 2 , and Fd molecules.
  • Smaller antibody fragments such as fragments of Fvs and fragments of Fabs, are also included in the term "fragments", as long as they retain the binding characteristics ofthe original antibody or larger fragment. Examples of such fragments would be (1) a minibody, which comprises a fragment ofthe heavy chain only ofthe Fv, (2) a microbody, which comprises a small fractional unit of antibody heavy chain variable region (International Application No.
  • Constructs include, for example, multimers such as diabodies, triabodies, and tetrabodies.
  • the phrases "antibody, or fragment thereof, or complex having an antibody, or fragment thereof and “antibody or fragment” are intended to encompass all of these molecules, as well as derivatives and homologs, mimetics, and variants thereof, unless it is specified otherwise or indicated otherwise based on context and/or knowledge in the art.
  • scFv monomers are designed with the C-terminal end ofthe VH domain tethered by a polypeptide linker to the N-terminal residue ofthe V L -
  • an inverse orientation is employed: the C-terminal end ofthe V L domain is tethered to the N-terminal residue of V H through a polypeptide linker (Power et al., J. Immun. Meth. 242: 193-204 (2000)).
  • the polypeptide linker is typically around fifteen amino acids in length. When the linker is reduced to about three to seven amino acids, the scFvs can not fold into a functional Fv domain and instead associate with a second scFv to form a diabody. Further reducing the length ofthe linker to less than three amino acids forces the scFv association into trimers or tetramers, depending on the linker length, composition and Fv domain orientations. (Powers (2000), supra).
  • an scFv may be employed as a blocking agent to bind a target receptor and thus block the binding ofthe "natural" ligand.
  • this higher affinity may be useful when the target receptors are involved in adhesion and rolling or when the target receptors are on cells present in areas of high sheer flow, such as platelets.
  • modifications such as those made to produce more stable antibodies or fragments may also be made to antibodies or fragments without altering their specificity.
  • peptoid modification semipeptoid modification, cyclic peptide modification, N terminus modification, C terminus modification, peptide bond modification, backbone modification, and residue modification may be performed. It is also within the ability ofthe skilled worker following the guidance ofthe present specification to test the modified antibodies or fragments to assess whether their binding characteristics have been changed.
  • addition antibodies can be isolated using the biopanning methods described herein, wherein a molecule or cell that binds to fixed human platelets or leukemic cells is used to screen a particular phage display library, particularly a library prepared from a leukemia, lymphoma, or myeloma patient.
  • antibodies that bind to an epitope present on at least one cell type involved in inflammation or tumorigenesis including B-CLL cells, T- ALL cells, AML cells, B-leukemia cells, multiple myeloma cells, and metastatic cells.
  • antibodies that bind to epitopes on a lipid, carbohydrate, peptide, glycolipid, glycoprotein, lipoprotein, and/or lipopolysaccharide molecule, wherein the epitopes preferably have at least one sulfated moiety can be determined using conventional methods.
  • binding data can be determined using biosensor analysis, e.g., using a commercial biosensor, BIACORE (Piscataway, N.J.) (Myszka, J. Mol. Recognition, 12: 279-84 (1999); Malmborg & Borrebaeck, J. Immunol Meth., 183: 7-13 (1999)).
  • biosensor analysis e.g., using a commercial biosensor, BIACORE (Piscataway, N.J.) (Myszka, J. Mol. Recognition, 12: 279-84 (1999); Malmborg & Borrebaeck, J. Immunol Meth., 183: 7-13 (1999)).
  • an scFv is defined as a molecule which is made up of a variable region of a heavy chain of a human antibody and a variable region of a light chain of a human antibody, which may be the same or different, and in which the variable region ofthe heavy chain is connected, linked, fused, or covalently attached to, or associated with, the variable region ofthe light chain.
  • An scFv construct may be a multimer (e.g., dimer, trimer, tetramer, and the like) of scFv molecules that incorporate one or more ofthe hypervariable domains ofthe antibody. All scFv derived constructs and fragments retain enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells. The binding selectivity and or specificity is primarily determined by hypervariable regions.
  • the antibodies ofthe subject invention can be constructed to fold into multivalent Fv forms, which may improve binding affinity and specificity and increased half-life in blood.
  • the phage library (as described herein above) can be designed to display scFvs, which can fold into the monovalent form ofthe Fv region of an antibody.
  • the construct is suitable for bacterial expression.
  • the genetically engineered scFvs comprise heavy chain and light chain variable regions joined by a contiguously encoded 15 amino acid flexible peptide spacer.
  • the preferred spacer is (Gly 4 Ser) 3 .
  • the length of this spacer, along with its amino acid, constituents provides for a nonbulky spacer, which allows the V H and the V L regions to fold into a functional Fv domain that provides effective binding to its target.
  • Varying the length ofthe spacers is yet another preferred method of forming dimers, trimers, and triamers (often referred to in the art as diabodies, triabodies, and tetrabodies, respectively). Dimers are formed under conditions where the spacer joining the two variable chains of an scFv is shortened to generally 5-12 amino acid residues. This shortened spacer prevents the two variable chains from the same molecule from folding into a functional Fv domain. Instead, the domains are forced to pair with complimentary domains of another molecule to create two binding domains. In a preferred method, a spacer of only 5 amino acids (Gly 4 Ser) was used for diabody construction. This dimer can be formed from two identical scFvs, or from two different populations of scFvs and retain the selective and/or specific enhanced binding activity of the parent scFv(s), and/or show increased binding strength or affinity.
  • triabodies are formed under conditions where the spacer joining the two variable chains of an scFv is shortened to generally less than 5 amino acid residues, preventing the two variable chains from the same molecule from folding into a functional Fv domain. Instead, three separate scFv molecules associate to form a trimer. In a preferred method, triabodies were obtained by completely removing this flexible spacer.
  • the triabody can be formed from three identical scFvs, or from two or three different populations of scFvs, and retain the selective and/or specific enhanced binding activity ofthe parent scFv(s), and/or show increased binding strength or affinity.
  • Tetrabodies are similarly formed under conditions where the spacer joining the two variable chains of an scFv is shortened to generally less than 5 amino acid residues, preventing the two variable chains from the same molecule from folding into a functional Fv domain. Instead, four separate scFv molecules associate to form a tetramer.
  • the tetrabody can be formed from four identical scFvs, or from 1 - 4 individual units from different populations of scFvs and should retain the selective and/or specific enhanced binding activity ofthe parent scFv(s), and/or show increased binding strength or affinity. Whether triabodies or tetrabodies form, under conditions where the spacer is generally less than 5 amino acid residues long, depends on the amino acid sequence ofthe particular scFv(s) in the mixture and the reaction conditions.
  • Antibodies, fragments thereof or constructs thereof, peptides, polypeptides, proteins, and fragments and constructs thereof can be produced in either prokaryotic or eukaryotic expression systems. Methods for producing antibodies and fragments in prokaryotic and eukaryotic systems are well-known in the art.
  • a eukaryotic cell system refers to an expression system for producing peptides or polypeptides by genetic engineering methods, wherein the host cell is a eukaryote.
  • a eukaryotic expression system may be a mammalian system, and the peptide or polypeptide produced in the mammalian expression system, after purification, is preferably substantially free of mammalian contaminants.
  • Other examples of a useful eukaryotic expression system include yeast expression systems.
  • a preferred prokaryotic system for production ofthe peptide or polypeptide ofthe invention uses E. coli as the host for the expression vector.
  • the peptide or polypeptide produced in the E. coli system, after purification, is substantially free of E. coli contaminating proteins.
  • Use of a prokaryotic expression system may result in the addition of a methionine residue to the N-terminus of some or all ofthe sequences provided for in the present invention. Removal ofthe N-terminal methionine residue, after peptide or polypeptide production to allow for full expression ofthe peptide or polypeptide, can be performed as is known in the art, one example being with the use of Aeromonas aminopeptidase under suitable conditions (U.S. Patent No. 5,763,215).
  • Antibodies and fragments may also have a tag that may be inserted or attached thereto to aid in the preparation and identification thereof, and in diagnostics.
  • the tag can later be removed from the molecule.
  • useful tags include: AUl, AU5, BTag, c-myc, FLAG, Glu-Glu, HA, His6, HSV, HTTPHH, IRS, KT3, Protein C, S-TAG®, T7, V5, and VSV-G (Jarvik and Telmer, Ann. Rev. Gen., 32, 601-18 (1998)).
  • the tag is preferably c-myc or KAK.
  • any suitable agent can be used in the compositions ofthe present invention.
  • Such agents generally have anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti- adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, antibacterial, anti-viral, or anti-inflammatory activity.
  • the agents ofthe present inventive compositions can be anti-cancer agents, anti-neoplastic agents, anti-viral agents, anti-metastatic agents, anti-inflammatory agents, anti-thrombosis agents, anti-restenosis agents, anti-aggregation agents, anti-autoimmune agents, anti-adhesion agents, anti- cardiovascular disease agents, or other anti-disease agents or pharmaceutical agent.
  • a pharmaceutical agent refers to an agent that is useful in the prophylactic treatment or diagnosis of a mammal including, but not restricted to, a human, bovine, equine, porcine, murine, canine, feline, or any other warm-blooded animal.
  • anti-viral agents including acyclovir, ganciclovir and zidovudine
  • anti-thrombosis/restenosis agents including cilostazol, dalteparin sodium, reviparin sodium, and aspirin
  • anti-inflammatory agents including zaltoprofen, pranoprofen, droxicam, acetyl salicylic 17, diclofenac, ibuprofen, dexibuprofen, sulindac, naproxen, amtolmetin, celecoxib, indomethacin, rofecoxib, and nimesulid
  • anti-autoimmune agents including leflunomide, denileukin diftitox, subreum, WinRho SDF, defibrotide, and cyclophosphamide
  • anti- adhesion/anti-aggregation agents including limaprost, clorcromene
  • exemplary pharmaceutical agents include cis-platinum, taxol, calicheamicin, vincristine, cytarabine (Ara-C), cyclophosphamide, prednisone, fludarabine, chlorambucil, interferon alpha, hydroxyurea, temozolomide, thalidomide and bleomycin, and derivatives and combinations thereof.
  • the pharmaceutical agent is an anthracycline or a derivative thereof; more preferably, the pharmaceutical agent is doxorubicin (adriamycin), daunorubicin, idarubicin, morpholinodoxorubicin, morpholinodaunorubicin, or methoxymorpholinyldoxorubicin, or derivatives and combinations thereof; and most preferably, the pharmaceutical agent is doxorubicin (adriamycin).
  • An anti-cancer agent is an agent with anti-cancer activity.
  • anti- cancer agents include agents that inhibit or halt the growth of cancerous or immature pre- cancerous cells, agents that kill cancerous or pre-cancerous, agents that increase the susceptibility of cancerous or pre-cancerous cells to other anti-cancer agents, and agents that inhibit metastasis of cancerous cells.
  • an anti-cancer agent may also be agent with anti-angiogenic activity that prevents, inhibits, retards, or halts vascularization of tumors.
  • Inhibition of growth of a cancer cell includes, for example, the (i) prevention of cancerous or metastatic growth, (ii) slowing down ofthe cancerous or metastatic growth, (iii) the total prevention ofthe growth process ofthe cancer cell or the metastatic process, while leaving the cell intact and alive, (iv) interfering contact of cancer cells with the microenvironment, or (v) killing the cancer cell.
  • An anti-leukemia agent is an agent with anti-leukemia activity.
  • anti- leukemia agents include agents that inhibit or halt the growth of leukemic or immature pre-leukemic cells, agents that kill leukemic or pre-leukemic, agents that increase the susceptibility of leukemic or pre-leukemic cells to other anti-leukemia agents, and agents that inhibit metastasis of leukemic cells.
  • an anti-leukemia agent may also be agent with anti-angiogenic activity that prevents, inhibits, retards or halts vascularization of tumors.
  • Inhibition of growth of a leukemia cell includes, for example, the (i) prevention of leukemic or metastatic growth, (ii) slowing down ofthe leukemic or metastatic growth, (iii) the total prevention ofthe growth process ofthe leukemia cell or the metastatic process, while leaving the cell intact and alive, (iv) interfering contact of cancer cells with the microenvironment, or (v) killing the leukemia cell.
  • Examples of anti-disease, anti-cancer, and anti-leukemic agents to which antibodies and fragments ofthe present invention may usefully be linked include toxins, radioisotopes, and pharmaceuticals.
  • toxins examples include gelonin, Pseudomonas exotoxin (PE), PE40, PE38, diphtheria toxin, ricin, or modifications or derivatives thereof.
  • radioisotopes examples include gamma-emitters, positron-emitters, and x-ray emitters that may be used for localization and/or therapy, and beta-emitters and alpha-emitters that may be used for therapy. The radioisotopes described previously as useful for diagnostics are also useful for therapeutics.
  • Non-limiting examples of anti-cancer or anti-leukemia pharmaceutical agents include doxorubicin (adriamycin), cis-platinum, taxol, calicheamicin, vincristine, cytarabine (Ara-C), cyclophosphamide, prednisone, daunorubicin, idarubicin, fludarabine, chlorambucil, interferon alpha, hydroxyurea, temozolomide, thalidomide, and bleomycin, and derivatives thereof, and combinations or modifications thereof.
  • anti-disease, anti-cancer or anti-leukemia agents can also be growth factor receptor antagonists, which inhibit stimulation of a growth factor receptor by a growth factor receptor ligand, thereby inhibiting growth of cells that express the growth factor receptor.
  • growth factor receptors are the receptors for epidermal growth factor (EGFR), vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), insulin-like growth factor (IGFR), nerve growth factor (NGFR), and fibroblast growth factor (FGF).
  • the antibodies and fragments thereof of the subject invention can also be optionally associated, complexed, or combined with or conjugated, fused, or linked to a pharmaceutically effective carrier.
  • carriers useful in the invention include dextran, lipophilic polymers, such as HPMA, and hydrophilic polymers.
  • decorated liposomes can be used, such as liposomes decorated with scFv Yl molecules, e.g., Doxil, a commercially available liposome containing large amounts of doxorubicin.
  • Such liposomes can be prepared to contain one or more desired pharmaceutical agents and be admixed with the antibodies ofthe present invention to provide a high drug to antibody ratio.
  • the vehicle or carrier is a doxorubicin-decorated liposome.
  • the vehicle or carrier is the hydrophilic polymer polyethylene glycol (PEG) or dextran.
  • the link between the antibody or fragment thereof and the pharmaceutical agent may be a direct link.
  • a direct link between two or more neighboring molecules may be produced via a chemical bond between elements or groups of elements in the molecules.
  • the chemical bond can be, for example, an ionic bond, a covalent bond, a hydrophobic bond, a hydrophilic bond, an electrostatic bond, or a hydrogen bond.
  • the bonds can be, for example, amine, carboxy, amide, hydroxyl, peptide, and/or disulf ⁇ de bonds.
  • the direct link may preferably be a protease resistant bond.
  • linker compound is defined as a compound that joins two or more moieties.
  • the linker can be straight-chained or branched.
  • a branched linker compound may be composed of a double-branch, triple branch, or quadruple or more branched compound.
  • Linker compounds useful in the present invention include those selected from the group having dicarboxylic acids, malemido hydrazides, PDPH, carboxylic acid hydrazides, and small peptides.
  • linker compounds useful, according to the present invention include: (a) dicarboxylic acids such as succinic acid, glutaric acid, and adipic acid; (b) maleimido hydrazides such as N-[maleimidocaproic acid] hydrazide, 4-[N- maleimidomethyl]cyclohexan-l-carboxylhydrazide, and N-[maleimidoundcanoic acid] hydrazide; (c) PDPH linkers such as (3-[2-pyridyldithio]propionyl hydrazide) conjugated to sulfurhydryl reactive protein; and (d) carboxylic acid hydrazides selected from 2-5 carbon atoms.
  • dicarboxylic acids such as succinic acid, glutaric acid, and adipic acid
  • maleimido hydrazides such as N-[maleimidocaproic acid] hydrazide, 4-[N- maleimidomethyl]cyclohex
  • Linking via direct coupling using small peptide linkers is also useful.
  • direct coupling between the free sugar of, for example, the anti-cancer drug doxorubicin and an scFv may be accomplished using small peptides.
  • small peptides include AUl, AU5, BTag, c-myc, FLAG, Glu-Glu, HA, His6, HSV, HTTPHH, IRS, KT3, Protein C, S-TAG ® , T7, V5, VSV-G, and KAK.
  • Antibodies, and fragments thereof, ofthe present invention may be bound to, conjugated to, complexed with, or otherwise associated with imaging agents (also called indicative markers), such as radioisotopes, and these conjugates can be used for diagnostic and imaging purposes. Kits having such radioisotope-antibody (or fragment) conjugates are provided.
  • radioisotopes useful for diagnostics include ⁇ ⁇ indium, U3 indium, 99m rhenium, ,05 rhenium, 10, rhenium, 99m technetium, 12l m tellurium, ,22m tellurium, I25m telluriunm I65 thulium, 167 thulium ,68 thulium 123 iodine, 126 iodine, 131 iodine, 133 iodine, 81m krypton, 33 xenon, 90 yttrium, 2,3 bismuth, 77 bromine, I8 fluorine, 95 ruthenium, 97 ruthenium, ruthenium, ruthenium, mercury, mercury, gallium, and gallium.
  • Preferred radioactive isotopes are opaque to X-rays or any suitable paramagnetic ions.
  • the indicative marker molecule may also be a fluorescent marker molecule.
  • fluorescent marker molecules include fluorescein, phycoerythrin, or rhodamine, or modifications or conjugates thereof.
  • Antibodies or fragments conjugated to indicative markers may be used to diagnose or monitor disease states. Such monitoring may be carried out in vivo, in vitro, or ex vivo. Where the monitoring or diagnosis is carried out in vivo or ex vivo, the imaging agent is preferably physiologically acceptable in that it does not harm the patient to an unacceptable level. Acceptable levels of harm may be determined by clinicians using such criteria as the severity ofthe disease and the availability of other options.
  • the present invention provides for a diagnostic kit for in vitro analysis of treatment efficacy before, during, or after treatment, having an imaging agent having a peptide ofthe invention linked to an indicative marker molecule, or imaging agent.
  • the invention further provides for a method of using the imaging agent for diagnostic localization and imaging of a cancer, more specifically a tumor, having the following steps: (a) contacting the cells with the composition; (b) measuring the radioactivity bound to the cells; and hence (c) visualizing the tumor.
  • imaging agents include fluorescent dyes, such as FITC, PE, and the like, and fluorescent proteins, such as green fluorescent proteins.
  • fluorescent proteins such as green fluorescent proteins.
  • Other examples include radioactive molecules and enzymes that react with a substrate to produce a recognizable change, such as a color change.
  • the imaging agent ofthe kit is a fluorescent dye, such as FITC, and the kit provides for analysis of treatment efficacy of cancers, more specifically blood- related cancers, e.g., leukemia, lymphoma, or myeloma. FACS analysis is used to determine the percentage of cells stained by the imaging agent and the intensity of staining at each stage ofthe disease, e.g., upon diagnosis, during treatment, during remission and during relapse.
  • the present invention also provides methods of ameliorating the effects of a disease, preventing a disease, treating a disease, or inhibiting the progress of a disease by administering to a patient in need thereof any ofthe present inventive compositions.
  • the present invention provides a method of inhibiting cell rolling, inflammation, auto-immune disease, thrombosis, restenosis, metastasis, growth and/or replication of tumor cells, growth and/or replication of leukemia cells, increase in the number of tumor cells in a patient having a tumor, or increase in the number of leukemia cells in a patient having leukemia.
  • the present invention provides methods of increasing the mortality rate of tumor cells, the mortality rate of leukemia cells, the susceptibility of diseased cells to damage by anti-disease agents, the susceptibility of tumor cells to damage by anti- cancer agents, or the susceptibility of leukemia cells to damage by anti-cancer agents. Further, the present invention provides methods of decreasing the number of tumor cells in a patient having a tumor, the number of leukemia cells in a patient having leukemia. Finally, the present invention provides methods of inhibiting cell-cell, cell-matrix, platelet- matrix, platelet-platelet, and/or cell-platelet complex formation, aggregation, or adhesion.
  • the present inventive methods are preferably carried out with one or both ofthe agent and antibody administered at an amount that is sub-clinical.
  • the present invention provides a method of therapeutic treatment that involves administering to a patient in need thereof (i) an antibody, or fragment thereof, and (ii) an agent, wherein one or both ofthe antibody, or fragment thereof, and/or the agent is administered in a sub- clinically effective amount. Amounts effective for this use will depend upon the severity ofthe disease and the general state ofthe patient's own immune system.
  • Dosing schedules will also vary with the disease state and status ofthe patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the treating physician and the patient's condition. It should be noted, however, that the present invention is not limited to any particular dose.
  • the methods ofthe present invention include administration ofthe agent and antibody in a single administration or multiple administrations, which can be such that the agent is administrated prior to, concurrently with, or subsequent to administration of the antibody, or fragment thereof.
  • the agent can be administered prior to, concurrently with, or subsequent to the antibody, or fragment thereof, or in any other sequence or arrangement and vice versa.
  • the agent and antibody can be present in separate compositions.
  • the antibodies, constructs, conjugates, combinations, and fragments ofthe subject invention may be administered to patients in need thereof via any suitable method.
  • Exemplary methods include intravenous, intramuscular, subcutaneous, topical, intratracheal, intrathecal, intraperitoneal, intralymphatic, nasal, sublingual, oral, rectal, vaginal, respiratory, buccal, intradermal, transdermal or intrapleural administration.
  • the formulation preferably will be prepared so that the amount administered to the patient will be an effective amount from about 0.1 mg to about 1000 mg ofthe desired composition. More preferably, the amount administered will be in the range of about 1 mg to about 500 mg ofthe desired composition.
  • the compositions ofthe invention are effective over a wide dosage range, and depend on factors such as the particulars ofthe disease to be treated, the half-life ofthe peptide or polypeptide-based pharmaceutical composition in the body ofthe patient, physical and chemical characteristics ofthe pharmaceutical agent and ofthe pharmaceutical composition, mode of administration ofthe pharmaceutical composition, particulars ofthe patient to be treated or diagnosed, as well as other parameters deemed important by the treating physician.
  • composition for oral administration may be in any suitable form. Examples include tablets, liquids, emulsions, suspensions, syrups, pills, caplets, and capsules. Methods of making pharmaceutical compositions are well known in the art. See, e.g., Remington, The Science and Practice of Pharmacy, Alfonso R. Gennaro (Ed.) Lippincott, Williams & Wilkins (pub).
  • the pharmaceutical composition may also be formulated so as to facilitate timed, sustained, pulsed, or continuous release.
  • the pharmaceutical composition may also be administered in a device, such as a timed, sustained, pulsed, or continuous release device.
  • the pharmaceutical composition for topical administration can be in any suitable form, such as creams, ointments, lotions, patches, solutions, suspensions, lyophylizates, and gels.
  • compositions comprising antibodies, constructs, conjugates, combination, and fragments ofthe subject invention may comprise conventional pharmaceutically acceptable diluents, excipients, carriers, and the like.
  • Tablets, pills, caplets and capsules may include conventional excipients such as lactose, starch and magnesium stearate.
  • Suppositories may include excipients such as waxes and glycerol.
  • injectable solutions comprise sterile pyrogen-free media such as saline, and may include buffering agents, stabilizing agents or preservatives. Conventional enteric coatings may also be used.
  • the present example examines the interaction between chemotherapy treatment and Yl in the MOLT-4 tumor-bearing mice.
  • Fig. 1 The results in Fig. 1 indicate that treatment with a sub-optimal dose of Dox, alone, had a negative effect on the survival of tumor-bearing mice (the mean survival time - MST is 33.5+1.68 days), relative to the control group (MTS 39.08 ⁇ 0.8 days).
  • the survival of mice sequentially treated with Dox, followed by Yl was highly significantly prolonged.
  • Yl alone had a dramatic effect on the survival rate of tumor-bearing mice
  • combination of sub-clinically optimal Dox+Yl had the best effect.
  • the significantly increased survival rate appears to be the result of a synergistic effect between chemotherapy and the Yl antibody.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions faisant intervenir un agent et un anticorps, ou un fragment dudit anticorps. Dans ces compositions, les agents, notamment des agents anti-cancéreux, anti-métastases, anti-leucémiques, anti-maladies, anti-adhérents, anti-thromboses, anti-resténoses, anti-maladies auto-immunes, anti-aggrégants, anti-bactériens, anti-viraux et anti-inflammatoires, peuvent être complexés ou combinés aux anticorps ou conjugués à ceux-ci, ou à des fragments de ceux-ci. En outre, l'agent et/ou l'anticorps, ou le fragment de celui-ci, peut être présent dans la composition à une quantité sous-clinique, qui est une quantité inférieure à la quantité de l'agent généralement efficace sur le plan clinique lorsque cet agent est administré seul. De préférence, dans ces compositions, l'agent est un agent anthracycline ou un dérivé de celui-ci, par exemple de la doxorubicine (adriamycin) ou un dérivé de celle-ci.
EP03742338A 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique Withdrawn EP1551452A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US189025 1988-05-02
US18902502A 2002-07-01 2002-07-01
PCT/US2003/020604 WO2004002528A1 (fr) 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique

Publications (2)

Publication Number Publication Date
EP1551452A1 true EP1551452A1 (fr) 2005-07-13
EP1551452A4 EP1551452A4 (fr) 2006-08-30

Family

ID=29999592

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03742338A Withdrawn EP1551452A4 (fr) 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique

Country Status (12)

Country Link
EP (1) EP1551452A4 (fr)
JP (1) JP2005534679A (fr)
KR (1) KR20050059001A (fr)
CN (1) CN1678348A (fr)
AU (1) AU2003279657A1 (fr)
BR (1) BR0312484A (fr)
CA (1) CA2491427A1 (fr)
IL (1) IL166062A0 (fr)
MX (1) MXPA05000271A (fr)
PL (1) PL374431A1 (fr)
RU (1) RU2005101622A (fr)
WO (1) WO2004002528A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (fr) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
WO2005094863A1 (fr) * 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Ameliorations dans le traitement du cancer et prediction efficace de traitement du cancer par le blocage et la detection d'inhibiteurs de la protease
US10092662B2 (en) * 2004-03-31 2018-10-09 University Of Utah Research Foundation Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
WO2010078916A1 (fr) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines pour thérapie tumorale avec agents chimiothérapiques
CN114767858A (zh) 2014-07-08 2022-07-22 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
TWI753875B (zh) * 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011918A1 (fr) * 1996-09-18 1998-03-26 Research Corporation Technologies, Inc. Utilisation d'anticorps contre les antigenes leucocytaires cd45 pour immunomodulation
WO2001085205A1 (fr) * 2000-05-11 2001-11-15 National Tsing Hua University Compositions et procedes concourant a l'induction d'une auto-immunite active
WO2001087334A1 (fr) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
WO2002059264A2 (fr) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Anticorps humains specifiques pour la therapie selective du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244987A (ja) * 1992-02-28 1993-09-24 Unitika Ltd 抗硫酸化チロシン抗体，その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ
JP2002520297A (ja) * 1998-07-13 2002-07-09 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム アミノリン脂質に結合する治療結合体を用いる癌処置方法
WO2000025808A1 (fr) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition de la differentiation des lymphocytes t cytotoxiques par des antagonistes du ligand de p-selectine (psgl)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011918A1 (fr) * 1996-09-18 1998-03-26 Research Corporation Technologies, Inc. Utilisation d'anticorps contre les antigenes leucocytaires cd45 pour immunomodulation
WO2001085205A1 (fr) * 2000-05-11 2001-11-15 National Tsing Hua University Compositions et procedes concourant a l'induction d'une auto-immunite active
WO2001087334A1 (fr) * 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
WO2002059264A2 (fr) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Anticorps humains specifiques pour la therapie selective du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004002528A1 *

Also Published As

Publication number Publication date
MXPA05000271A (es) 2005-03-31
BR0312484A (pt) 2008-01-08
AU2003279657A1 (en) 2004-01-19
WO2004002528A1 (fr) 2004-01-08
KR20050059001A (ko) 2005-06-17
JP2005534679A (ja) 2005-11-17
WO2004002528A9 (fr) 2004-11-18
IL166062A0 (en) 2006-01-15
CA2491427A1 (fr) 2004-01-08
EP1551452A4 (fr) 2006-08-30
CN1678348A (zh) 2005-10-05
PL374431A1 (en) 2005-10-17
RU2005101622A (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
US20090220486A1 (en) Antibodies and uses thereof
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
US20040202665A1 (en) Compositions and methods for therapeutic treatment
KR20030091953A (ko) 황산화된 부분을 함유하는 에피토프를 포함하는 분리된분자, 그러한 에피토프에 대한 항체, 및 그들의 용도
JP2005503756A5 (fr)
KR20030091952A (ko) 선택적인 암 치료용의 특이적 인간 항체
WO2004003166A2 (fr) Anticorps et leurs applications
US20050152906A1 (en) Specific human antibodies
EP1551452A1 (fr) Compositions et procedes pour traitement therapeutique
US20080274100A1 (en) Antibodies and uses thereof
EP1649001A2 (fr) Anticorps et utilisations de ceux-ci
WO2005005455A2 (fr) Anticorps humains specifiques
US20040208877A1 (en) Antibodies and uses thereof
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080710

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20060731

17Q First examination report despatched

Effective date: 20070705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080909

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080710

Country of ref document: HK